Canada markets open in 4 hours 16 minutes

Ceapro Inc. (CZO.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.4000+0.0400 (+11.11%)
At close: 03:49PM EDT
Full screen
Previous Close0.3600
Open0.3500
Bid0.3850 x 0
Ask0.4000 x 0
Day's Range0.3400 - 0.4000
52 Week Range0.3400 - 0.8200
Volume212,150
Avg. Volume39,873
Market Cap31.317M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateNov 07, 2023 - Nov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update

    - $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization - Ended the quarter with $11.3 million in cash allowing funding for planned pipeline and technology developments - Ongoing strategic corporate discussions progressing and continued planning for uplisting to Nasdaq EDMONTON, Alberta, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: C

  • GlobeNewswire

    Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

    – Exclusive agreement extended from 3 to 5 years until December 31, 2026 – Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market – Offering of new preservative free dry product formulation for oat beta glucan EDMONTON, Alberta, Aug. 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization o

  • GlobeNewswire

    Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation

    – New studies to focus on speed of healing and molecular profiling of tissue regeneration induced by oat-derived bioactive products – EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the expansion of its collaboration with the Angiogenesis Foundation to conduct re